Heron Therapeutics, Inc. · NASDAQ:HRTX
Heron Therapeutics — Q1 2025 Earnings Presentation
15 slides from Heron Therapeutics's earnings presentation, May 6, 2025
Slide 1: Heron Therapeutics Q1 2025 Earnings Call
Heron Therapeutics Q1 2025 Earnings Call May 6, 2025 1
Slide 2: Forward-looking Statements and Non-GAAP Disclosures
Forward-looking Statements and Non-GAAP Disclosures This presentation contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date h
Slide 3: Executive Summary
Executive Summary STRICTLY PRIVATE & CONFIDENTIAL 3
Slide 4: Q1 2025 Achievements and Key Updates
Q1 2025 Achievements and Key Updates 1 Generated Q1 2025 Net Revenue of $38.9 million 2 Achieved Q1 2025 Net Income of $2.6 million 3 Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties’ CINVANTI® and 4 APONVIE® patent l
Slide 5: Product Performance
Product Performance STRICTLY PRIVATE & CONFIDENTIAL 5
Slide 6: Oncology Care Franchise Net Sales
Oncology Franchise Oncology Care Franchise Net Sales 3 months ended March 31, 2025: $28.6 million CINVANTI® Net Sales SUSTOL® Net Sales +0.5% -21% 26.9 4.2 25.6 25.7 24.3 24.9 3.8 23.3 22.7 3.6 3.4 3.5 2.8 2.9 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2023 2023 2024 2024 2024 2024 2025 2023 2023 202
Slide 7: CINVANTI Performance Metrics and Growth Drivers
Oncology Franchise CINVANTI Performance Metrics and Growth Drivers CINVANTI – AVERAGE DAILY UNITS CINVANTI – ORDERING ACCOUNTS Key CINVANTI Growth Drivers 3,400 900 140 • Endorsed in NCCN Guidelines 3,300 850 120 • MOA-Driven Efficacy: 3,200 Broad coverage: Blocks signal 3,100 100 transmission at th
Slide 8: Acute Care Franchise Net Sales
Acute Care Franchise Acute Care Franchise Net Sales 3 months ended March 31, 2025: $10.3 million +60% +432% APONVIE ® Net Sales ZYNRELEF ® Net Sales 8.5 2.3 8.0 1.9 6.2 5.7 5.8 5.0 4.4 1.1 4.1 1.0 3.5 .5 ..43 .4 .3 .2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2023 2023 2023 2023 2024 202
Slide 9: APONVIE Performance Metrics and Growth Drivers
Acute Care Franchise APONVIE Performance Metrics and Growth Drivers APONVIE - AVERAGE DAILY UNITS APONVIE - ORDERING ACCOUNTS Key APONVIE Growth Drivers 1,000 250 • MOA-Driven Efficacy: 900 Broad coverage: Blocks signal transmission 800 200 at the final common receptor pathway to vomiting 700 Fast o
Slide 10: ZYNRELEF Performance Metrics and Growth Drivers
Acute Care Franchise ZYNRELEF Performance Metrics and Growth Drivers ZYNRELEF - AVERAGE DAILY UNITS ZYNRELEF - ORDERING ACCOUNTS Key ZYNRELEF Growth Drivers 1200 700 • Expanded Label: # of indicated 1100 procedures/formulary additions 650 • Crosslink Partnership: Awareness/OR 1000 education/maintena
Slide 11: Finance
Finance STRICTLY PRIVATE & CONFIDENTIAL 11
Slide 12: Select Financial Results
Select Financial Results (Unaudited) In $K QTD QTD Q1 2025 Q1 2024 Net Product Sales $ 38,903 $ 34,670 Cost of Product Sales 8,457 8,444 Gross profit 30,446 26,226 Operating Expenses: Research and development 2,279 4,608 General and administrative 12,702 14,974 Sales and marketing 12,311 11,442 Tota
Slide 13: Adjusted EBITDA
Adjusted EBITDA U.S. GAAP to Non-GAAP Reconciliation (unaudited) In $K QTD QTD Q1 2025 Q1 2024 Net Income (loss) $ 2,635 $ (3,160) Other expense (income), net 519 (1,638) Depreciation 551 689 Stock-based compensation 2,511 3,375 Adjusted EBITDA $ 6,216 $ (734) 13
Slide 14: Revised 2025 Guidance
Revised 2025 Guidance Product Revenues, Net $153.0 – $163.0 million Adjusted EBITDA^ $4.0 - $12.0 million ^ Excludes Stock-Based Compensation, Depreciation and Amortization 14
Slide 15: Questions
THERAPEUTICS’ Questions 15